PMV Pharmaceuticals, Inc.
PMVP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1,144 | $1,257 | $650 | $1,281 |
| Gross Profit | -$1,144 | -$1,257 | -$650 | -$1,281 |
| % Margin | – | – | – | – |
| R&D Expenses | $57,383 | $54,628 | $51,673 | $36,186 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $26,921 | $24,247 | $24,717 | $20,826 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $84,304 | $78,875 | $76,390 | $57,012 |
| Operating Income | -$85,448 | -$80,132 | -$77,040 | -$58,293 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $10,639 | $11,174 | $3,714 | $470 |
| Pre-Tax Income | -$74,809 | -$68,958 | -$73,326 | -$57,823 |
| Tax Expense | -$16,100 | $2 | -$9 | $23 |
| Net Income | -$58,709 | -$68,960 | -$73,317 | -$57,846 |
| % Margin | – | – | – | – |
| EPS | -1.138 | -1.44 | -1.61 | -1.28 |
| % Growth | 21% | 10.6% | -25.8% | – |
| EPS Diluted | -1.138 | -1.44 | -1.61 | -1.28 |
| Weighted Avg Shares Out | 51,579 | 48,014 | 45,595 | 45,138 |
| Weighted Avg Shares Out Dil | 51,579 | 48,015 | 45,595 | 45,138 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,655 | $11,171 | $3,627 | $449 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,144 | $1,257 | $650 | $1,281 |
| EBITDA | -$73,665 | -$67,701 | -$72,676 | -$56,542 |
| % Margin | – | – | – | – |